Lacosta, Ana-María Pascual-Lucas, María Pesini, Pedro Casabona, Diego Pérez-Grijalba, Virginia Marcos-Campos, Iván Sarasa, Leticia Canudas, Jesus Badi, Hassnae Monleón, Inmaculada San-José, Itziar Munuera, Josep Rodríguez-Gómez, Octavio Abdelnour, Carla Lafuente, Asunción Buendía, Mar Boada, Mercè Tárraga, Lluis Ruiz, Agustín Sarasa, Manuel Additional file 4: Table S2. of Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial Relationship of adverse events (AEs) with the treatment. (DOCX 15 kb) Alzheimer’s disease;Amyloid-β;Aβ;Immunotherapy;ABvac40;Phase I 2018-01-29
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_4_Table_S2_of_Safety_tolerability_and_immunogenicity_of_an_active_anti-A_40_vaccine_ABvac40_in_patients_with_Alzheimer_s_disease_a_randomised_double-blind_placebo-controlled_phase_I_trial/5835027
10.6084/m9.figshare.5835027.v1